The efficacy and safety of CAG regimen for newly diagnosed adult T-cell acute lymphoblastic leukemia/ T lymphoblastic lymphoma-a prospective, one-arm, multi-center, pilot study

The efficacy and safety of CAG regimen for newly diagnosed adult t-cell acute lymphoblastic leukemia/ T lymphoblastic lymphoma-a prospective, one-arm, multi-center, pilot study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032101

Enrollment

Unknown

Registered

2020-04-20

Start date

2020-04-15

Completion date

Unknown

Last updated

2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T-cell acute lymphoblastic leukemia/ lymphoma

Interventions

Case series:CAG regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) initial diagnosis of T-ALL/LBL. Diagnostic criteria refer to 2016 WHO classification; 2) aged >=18 years; 3) the ECOG physical fitness score 0-3; 4) life expectancy >8 weeks; 5) able to provide informed consent, understand and comply with the requirements of the study.

Exclusion criteria

Exclusion criteria: 1) pregnant or lactating women. 2) unable to understand or follow the research protocol or unable to sign the informed consent.

Design outcomes

Primary

Measure	Time frame
CR+CRi after one cycle;	—

Secondary

Measure	Time frame
Hematological and non-hematological adverse events;Monitoring of minimal residual disease (MRD);Hospital costs;Length of stay;Overall survival (OS);	—

Countries

China

Contacts

Public ContactHong-Hu Zhu

the First Affiliated Hospital of Medical School of Zhejiang University

zhuhhdoc@163.com+86 13671232272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026